Unicycive Therapeutics Inc (UNCY) - Net Assets
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has net assets worth $53.27 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($72.03 Million) and total liabilities ($18.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Unicycive Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $53.27 Million |
| % of Total Assets | 73.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | 83.19% |
| 10-Year Change | N/A |
| Growth Volatility | 204.6 |
Unicycive Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Unicycive Therapeutics Inc.
Annual Net Assets for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Unicycive Therapeutics Inc from 2018 to 2025. Also explore UNCY net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $30.20 Million | +306.37% |
| 2024-12-31 | $7.43 Million | +295.09% |
| 2023-12-31 | $-3.81 Million | -717.38% |
| 2022-12-31 | $-466.00K | -102.83% |
| 2021-12-31 | $16.48 Million | +717.15% |
| 2020-12-31 | $-2.67 Million | -202.15% |
| 2019-12-31 | $-884.00K | +26.70% |
| 2018-12-31 | $-1.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Unicycive Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12633200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.00K | 0.07% |
| Other Comprehensive Income | $-1.00K | 0.00% |
| Other Components | $158.00 Million | 523.23% |
| Total Equity | $30.20 Million | 100.00% |
Unicycive Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Unicycive Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FinLab AG
F:A7A
|
$130.67 Million |
|
Tecogen Inc.
NYSE:TGEN
|
$130.69 Million |
|
Horizon Copper Corp.
V:HCU
|
$130.74 Million |
|
Agora S.A.
WAR:AGO
|
$130.76 Million |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
$130.64 Million |
|
Paragon Care Limited
F:PXS
|
$130.61 Million |
|
Surteco Group SE
XETRA:SUR
|
$130.52 Million |
|
First Farms A/S
CO:FFARMS
|
$130.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Unicycive Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,431,000 to 30,197,000, a change of 22,766,000 (306.4%).
- Net loss of 26,555,000 reduced equity.
- New share issuances of 46,582,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 2,740,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.55 Million | -87.94% |
| Share Issuances | $46.58 Million | +154.26% |
| Other Comprehensive Income | $-1.00K | -0.0% |
| Other Changes | $2.74 Million | +9.07% |
| Total Change | $- | 306.37% |
Book Value vs Market Value Analysis
This analysis compares Unicycive Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.52 | $4.77 | x |
| 2019-12-31 | $-1.04 | $4.77 | x |
| 2020-12-31 | $-1.75 | $4.77 | x |
| 2021-12-31 | $14.12 | $4.77 | x |
| 2022-12-31 | $-0.31 | $4.77 | x |
| 2023-12-31 | $-1.55 | $4.77 | x |
| 2024-12-31 | $1.11 | $4.77 | x |
| 2025-12-31 | $1.90 | $4.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Unicycive Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.63x
- Recent ROE (-87.94%) is below the historical average (-80.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-999.40K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.22 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.24 Million |
| 2021 | -64.50% | 0.00% | 0.00x | 1.14x | $-12.28 Million |
| 2022 | 0.00% | -1899.47% | 0.34x | 0.00x | $-18.02 Million |
| 2023 | 0.00% | -4525.04% | 0.05x | 0.00x | $-30.16 Million |
| 2024 | -494.27% | 0.00% | 0.00x | 4.26x | $-37.47 Million |
| 2025 | -87.94% | 0.00% | 0.00x | 1.63x | $-29.57 Million |
Industry Comparison
This section compares Unicycive Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Unicycive Therapeutics Inc (UNCY) | $53.27 Million | 0.00% | 0.35x | $130.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more